Cefquinome concentrations in endometrium after intrauterine treatment of cobactan 4.5% in mares and inflammatory response of the endometrium to this treatment.
This study was conducted to measure the concentration of cefquinome in the endometrium of mares after intrauterine treatment and to evaluate associated inflammation. Mares (n = 14) were randomly assigned to one of the following groups: (i) control (n = 4) were either not treated (n = 2) or received (n = 2) lactated Ringer's intrauterine for 1 or 3 days; (ii) treated mares (n = 10) received intrauterine cefquinome for 1 or 3 days. After at least 10 days had passed following the last treatment and ovulation, mares were given Prostaglandin F2alpha (PGF2alpha) and were randomly assigned to an alternate treatment. Endometrial biopsy samples were taken at 2, 8, 24 and 48 h, or at 4, 12 and 36 h, after the last treatment. Biopsy samples were taken at the same time points from control mares (n = 2) and lactated Ringer-treated mares (n = 2). Cefquinome concentrations were quantified using a high-performance liquid chromatography (HPLC) assay and inflammation was assessed using haematoxylin and eosin (H&E)-stained sections. Concentrations of cefquinome [559 (1 day) and 595 microg/g (3 days) at 2 h, and 403 (1 day) and 370 microg/g (3 days) at 4 h] were similar between treatment groups at 2 and 4 h after treatment (p > 0.05). At 8 h, as well as at 24 and 48 h, concentrations were greater in the 3-day group (17 vs 301 microg/g, 3 vs 80 microg/g and 0.1 vs 0.2 microg/g, respectively) (p < 0.05). No significant differences (p > 0.05) in the inflammatory response at 2-48 h after treatment were found between groups.
Parlevliet
J M
JM
Department of Farm Animal Health, Utrecht University, Utrecht, The Netherlands.
Paccamonti
D L
DL
Barker
S A
SA
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000032:analysis; D001706:Biopsy / Q000662:veterinary; D002511:Cephalosporins / Q000008:administration & dosage* / Q000009:adverse effects / Q000032:analysis*; D004716:Endometritis / Q000139:chemically induced* / Q000473:pathology; D004717:Endometrium / Q000737:chemistry*; D005260:Female; D006734:Horse Diseases / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D006736:Horses; D014599:Uterus / Q000187:drug effects / Q000473:pathology
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; C068212:cefquinome